Structural elements of primary CCR5-using HIV-1 gp120 proteins influencing sensitivity and resistance to the broadly neutralizing monoclonal antibody b12

Virology

Volumn 432, Issue 2, 2012, Pages 394-404

  Sterjovski, Jasminka ^a   Churchill, Melissa J ^a,b   Ellett, Anne ^a   Wesselingh, Steve L ^c   Ramsland, Paul A ^a,b,d   Gorry, Paul R ^a,b,d  

^a BURNET INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

B12; Gp120; HIV 1; Neutralization; Structure

Indexed keywords

CHEMOKINE RECEPTOR CCR5; GLYCOPROTEIN GP 120; MONOCLONAL ANTIBODY B12;

ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; BINDING SITE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN POLYMORPHISM; PROTEIN STRUCTURE; STRUCTURE ANALYSIS; VIRUS NEUTRALIZATION;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; BINDING SITES; EPITOPE MAPPING; EPITOPES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; IMMUNOGLOBULIN G; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; RECEPTORS, CCR5;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84865303160     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2012.06.024     Document Type: Article

References (72)

1. Bublil E.M., Yeger-Azuz S., Gershoni J.M. Computational prediction of the cross-reactive neutralizing epitope corresponding to the [corrected] monclonal [corrected] antibody b12 specific for HIV-1 gp120. Faseb J. 2006, 20:1762-1774.
2. Burton D.R., Barbas C.F., Persson M.A., Koenig S., Chanock R.M., Lerner R.A. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc. Nat. Acad. Sci. U.S.A. 1991, 88:10134-10137.
3. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W., Sawyer L.S., Hendry R.M., Dunlop N., Nara P.L., et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994, 266:1024-1027.
4. Cashin K., Roche M., Sterjovski J., Ellett A., Gray L.R., Cunningham A.L., Ramsland P.A., Churchill M.J., Gorry P.R. Alternative coreceptor requirements for efficient CCR5- and CXCR4-mediated HIV-1 entry into macrophages. J. Virol. 2011, 85:10699-10709.
5. Chan D.C., Fass D., Berger J.M., Kim P.S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997, 89:263-273.
6. Chang M.I., Panorchan P., Dobrowsky T.M., Tseng Y., Wirtz D. Single-molecule analysis of human immunodeficiency virus type 1 gp120-receptor interactions in living cells. J. Virol. 2005, 79:14748-14755.
7. Dalgleish A.G., Beverley P.C., Clapham P.R., Crawford D.H., Greaves M.F., Weiss R.A. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984, 312:763-767.
8. Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., Di Marzio P., Marmon S., Sutton R.E., Hill C.M., Davis C.B., Peiper S.C., Schall T.J., Littman D.R., Landau N.R. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381:661-666.
9. Dey B., Pancera M., Svehla K., Shu Y., Xiang S.H., Vainshtein J., Li Y., Sodroski J., Kwong P.D., Mascola J.R., Wyatt R. Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity. J. Virol. 2007, 81:5579-5593.
10. Dragic T., Litwin V., Allaway G.P., Martin S.R., Huang Y., Nagashima K.A., Cayanan C., Maddon P.J., Koup R.A., Moore J.P., Paxton W.A. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996, 381:667-673.
11. Duenas-Decamp M.J., Peters P., Burton D., Clapham P.R. Natural resistance of human immunodeficiency virus type 1 to the CD4bs antibody b12 conferred by a glycan and an arginine residue close to the CD4 binding loop. J. Virol. 2008, 82:5807-5814.
12. Duenas-Decamp M.J., Peters P.J., Burton D., Clapham P.R. Determinants flanking the CD4 binding loop modulate macrophage tropism of human immunodeficiency virus type 1 R5 envelopes. J. Virol. 2009, 83:2575-2583.
13. Dunfee R.L., Thomas E.R., Gorry P.R., Wang J., Taylor J., Kunstman K., Wolinsky S.M., Gabuzda D. The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia. Proc. Nat. Acad. Sci. U.S.A. 2006, 103:15160-15165.
14. Dunfee R.L., Thomas E.R., Wang J., Kunstman K., Wolinsky S.M., Gabuzda D. Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia. Virology 2007, 367:222-234.
15. Etemad-Moghadam B., Sun Y., Nicholson E.K., Fernandes M., Liou K., Gomila R., Lee J., Sodroski J. Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo. J. Virol. 2000, 74:4433-4440.
16. Feng Y., Broder C.C., Kennedy P.E., Berger E.A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272:872-877.
17. Gao F., Morrison S.G., Robertson D.L., Thornton C.L., Craig S., Karlsson G., Sodroski J., Morgado M., Galvao-Castro B., von Briesen H., Beddows S., Weber J., Sharp P.M., Shaw G.M., Hahn B.H. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization. J. Virol. 1996, 70:1651-1667.
18. Gorry P.R., Dunfee R.L., Mefford M.E., Kunstman K., Morgan T., Moore J.P., Mascola J.R., Agopian K., Holm G.H., Mehle A., Taylor J., Farzan M., Wang H., Ellery P., Willey S.J., Clapham P.R., Wolinsky S.M., Crowe S.M., Gabuzda D. Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote. Virology 2007, 362:163-178.
19. Gorry P.R., Howard J.L., Churchill M.J., Anderson J.L., Cunningham A., Adrian D., McPhee D.A., Purcell D.F. Diminished production of human immunodeficiency virus type 1 in astrocytes results from inefficient translation of gag, env, and nef mRNAs despite efficient expression of Tat and Rev. J. Virol. 1999, 73:352-361.
20. Gorry P.R., Taylor J., Holm G.H., Mehle A., Morgan T., Cayabyab M., Farzan M., Wang H., Bell J.E., Kunstman K., Moore J.P., Wolinsky S.M., Gabuzda D. Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J. Virol. 2002, 76:6277-6292.
21. Gray L., Churchill M.J., Keane N., Sterjovski J., Ellett A.M., Purcell D.F., Poumbourios P., Kol C., Wang B., Saksena N.K., Wesselingh S.L., Price P., French M., Gabuzda D., Gorry P.R. Genetic and functional analysis of R5×4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous for the CCR5delta32 allele. J. Virol. 2006, 80:3684-3691.
22. Gray L., Roche M., Churchill M.J., Sterjovski J., Ellett A., Poumbourios P., Sheffief S., Wang B., Saksena N., Purcell D.F., Wesselingh S., Cunningham A.L., Brew B.J., Gabuzda D., Gorry P.R. Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain. J. Virol. 2009, 83:5430-5441.
23. Gray L., Sterjovski J., Churchill M., Ellery P., Nasr N., Lewin S.R., Crowe S.M., Wesselingh S.L., Cunningham A.L., Gorry P.R. Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome. Virology 2005, 337:384-398.
24. Kozarsky K., Penman M., Basiripour L., Haseltine W., Sodroski J., Krieger M. Glycosylation and processing of the human immunodeficiency virus type 1 envelope protein. J. Acquir. Immune. Defic. Syndr. 1989, 2:163-169.
25. Krissinel E., Henrick K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 2007, 372:774-797.
26. Kwong P.D., Doyle M.L., Casper D.J., Cicala C., Leavitt S.A., Majeed S., Steenbeke T.D., Venturi M., Chaiken I., Fung M., Katinger H., Parren P.W., Robinson J., Van Ryk D., Wang L., Burton D.R., Freire E., Wyatt R., Sodroski J., Hendrickson W.A., Arthos J. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002, 420:678-682.
27. Kwong P.D., Wyatt R., Majeed S., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Struct. Fold. Des. 2000, 8:1329-1339.
28. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393:648-659.
29. Kwong P.D., Wyatt R., Sattentau Q.J., Sodroski J., Hendrickson W.A. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J. Virol. 2000, 74:1961-1972.
30. Li Y., O'Dell S., Walker L.M., Wu X., Guenaga J., Feng Y., Schmidt S.D., McKee K., Louder M.K., Ledgerwood J.E., Graham B.S., Haynes B.F., Burton D.R., Wyatt R.T., Mascola J.R. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J. Virol. 2011, 85:8954-8967.
31. Liu J., Bartesaghi A., Borgnia M.J., Sapiro G., Subramaniam S. Molecular architecture of native HIV-1 gp120 trimers. Nature 2008, 455:109-113.
32. Ly A., Stamatatos L. V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies. J. Virol. 2000, 74:6769-6776.
33. McCaffrey R.A., Saunders C., Hensel M., Stamatatos L. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies. J. Virol. 2004, 78:3279-3295.
34. McInerney T.L., McLain L., Armstrong S.J., Dimmock N.J. A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a postfusion event. Virology 1997, 233:313-326.
35. Moore J.P., Cao Y., Qing L., Sattentau Q.J., Pyati J., Koduri R., Robinson J., Barbas C.F., Burton D.R., Ho D.D. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 1995, 69:101-109.
36. Muster T., Guinea R., Trkola A., Purtscher M., Klima A., Steindl F., Palese P., Katinger H. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J. Virol. 1994, 68:4031-4034.
37. Nabatov A.A., Pollakis G., Linnemann T., Kliphius A., Chalaby M.I., Paxton W.A. Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies. J. Virol. 2004, 78:524-530.
38. Pantophlet R., Ollmann Saphire E., Poignard P., Parren P.W., Wilson I.A., Burton D.R. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J. Virol. 2003, 77:642-658.
39. Parren P.W., Marx P.A., Hessell A.J., Luckay A., Harouse J., Cheng-Mayer C., Moore J.P., Burton D.R. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 2001, 75:8340-8347.
40. Parren P.W., Mondor I., Naniche D., Ditzel H.J., Klasse P.J., Burton D.R., Sattentau Q.J. Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. J. Virol. 1998, 72:3512-3519.
41. Platt E.J., Wehrly K., Kuhmann S.E., Chesebro B., Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 1998, 72:2855-2864.
42. Richman D.D., Wrin T., Little S.J., Petropoulos C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Nat. Acad. Sci. U.S.A. 2003, 100:4144-4149.
43. Rizzuto C.D., Wyatt R., Hernandez-Ramos N., Sun Y., Kwong P.D., Hendrickson W.A., Sodroski J. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 1998, 280:1949-1953.
44. Roben P., Moore J.P., Thali M., Sodroski J., Barbas C.F., Burton D.R. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol. 1994, 68:4821-4828.
45. Roche M., Jakobsen M.R., Ellett A., Salimiseyedabad H., Jubb B., Westby M., Lee B., Lewin S.R., Churchill M.J., Gorry P.R. HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry. Retrovirology 2011, 8:89.
46. Roche M., Jakobsen M.R., Sterjovski J., Ellett A., Posta F., Lee B., Jubb B., Westby M., Lewin S.R., Ramsland P.A., Churchill M.J., Gorry P.R. HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less efficient mechanism of gp120-CCR5 engagement that attenuates macrophage-tropism. J. Virol. 2011, 85:4330-4342.
47. Sali A., Blundell T.L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 1993, 234:779-815.
48. Sanders R.W., van Anken E., Nabatov A.A., Liscaljet I.M., Bontjer I., Eggink D., Melchers M., Busser E., Dankers M.M., Groot F., Braakman I., Berkhout B., Paxton W.A. The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion. Retrovirology 2008, 5:10.
49. Sattentau Q. HIV gp120: double lock strategy foils host defences. Structure 1998, 6:945-949.
50. Sattentau Q.J., Moore J.P. Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J. Exp. Med. 1991, 174:407-415.
51. Sattentau Q.J., Moore J.P. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J. Exp. Med. 1995, 182:185-196.
52. Steffens C.M., Hope T.J. Mobility of the human immunodeficiency virus (HIV) receptor CD4 and coreceptor CCR5 in living cells: implications for HIV fusion and entry events. J. Virol. 2004, 78:9573-9578.
53. Sterjovski J., Churchill M.J., Ellett A., Gray L.R., Roche M.J., Dunfee R.L., Purcell D.F., Saksena N., Wang B., Sonza S., Wesselingh S.L., Karlsson I., Fenyo E.M., Gabuzda D., Cunningham A.L., Gorry P.R. Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. Retrovirology 2007, 4:89.
54. Sterjovski J., Churchill M.J., Roche M., Ellett A., Farrugia W., Wesselingh S.L., Cunningham A.L., Ramsland P.A., Gorry P.R. CD4-binding site alterations in CCR5-using HIV-1 envelopes influencing gp120-CD4 interactions and fusogenicity. Virology 2011, 410:418-428.
55. Sterjovski J., Roche M., Churchill M.J., Ellett A., Farrugia W., Gray L.R., Cowley D., Poumbourios P., Lee B., Wesselingh S., Cunningham A.L., Ramsland P.A., Gorry P.R. An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes. Virology 2010, 404:269-278.
56. Thali M., Moore J.P., Furman C., Charles M., Ho D.D., Robinson J., Sodroski J. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 1993, 67:3978-3988.
57. Trkola A., Dragic T., Arthos J., Binley J.M., Olson W.C., Allaway G.P., Cheng-Mayer C., Robinson J., Maddon P.J., Moore J.P. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 1996, 384:184-187.
58. Trkola A., Pomales A.B., Yuan H., Korber B., Maddon P.J., Allaway G.P., Katinger H., Barbas C.F., Burton D.R., Ho D.D., et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 1995, 69:6609-6617.
59. Trkola A., Purtscher M., Muster T., Ballaun C., Buchacher A., Sullivan N., Srinivasan K., Sodroski J., Moore J.P., Katinger H. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol. 1996, 70:1100-1108.
60. Veazey R.S., Shattock R.J., Pope M., Kirijan J.C., Jones J., Hu Q., Ketas T., Marx P.A., Klasse P.J., Burton D.R., Moore J.P. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat. Med. 2003, 9:343-346.
61. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Kilby J.M., Saag M.S., Komarova N.L., Nowak M.A., Hahn B.H., Kwong P.D., Shaw G.M. Antibody neutralization and escape by HIV-1. Nature 2003, 422:307-312.
62. Wu L., Gerard N.P., Wyatt R., Choe H., Parolin C., Ruffing N., Borsetti A., Cardoso A.A., Desjardin E., Newman W., Gerard C., Sodroski J. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996, 384:179-183.
63. Wu X., Zhou T., O'Dell S., Wyatt R.T., Kwong P.D., Mascola J.R. Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment. J. Virol. 2009, 83:10892-10907.
64. Wyatt R., Kwong P.D., Desjardins E., Sweet R.W., Robinson J., Hendrickson W.A., Sodroski J.G. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998, 393:705-711.
65. Wyatt R., Moore J., Accola M., Desjardin E., Robinson J., Sodroski J. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J. Virol. 1995, 69:5723-5733.
66. Wyatt R., Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998, 280:1884-1888.
67. Wyatt R., Sullivan N., Thali M., Repke H., Ho D., Robinson J., Posner M., Sodroski J. Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. J. Virol. 1993, 67:4557-4565.
68. Yang X., Kurteva S., Lee S., Sodroski J. Stoichiometry of antibody neutralization of human immunodeficiency virus type 1. J. Virol. 2005, 79:3500-3508.
69. Yang X., Tomov V., Kurteva S., Wang L., Ren X., Gorny M.K., Zolla-Pazner S., Sodroski J. Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1. J. Virol. 2004, 78:12975-12986.
70. Yang X., Wyatt R., Sodroski J. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J. Virol. 2001, 75:1165-1171.
71. Zhou T., Xu L., Dey B., Hessell A.J., Van Ryk D., Xiang S.H., Yang X., Zhang M.Y., Zwick M.B., Arthos J., Burton D.R., Dimitrov D.S., Sodroski J., Wyatt R., Nabel G.J., Kwong P.D. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007, 445:732-737.
72. Zwick M.B., Parren P.W., Saphire E.O., Church S., Wang M., Scott J.K., Dawson P.E., Wilson I.A., Burton D.R. Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120. J. Virol. 2003, 77:5863-5876.